Abstract:Abstract Receptor activator of NF‐κB ligand (RANKL) stimulation leads to the activation of mitogen‐activated protein kinase (MAPK)/AP‐1 and Ca 2+ –nuclear factor of activated T‐cells cytoplasmic 1 (NFATc1) signaling pathways in osteoclastogenesis. Targeting these pathways has been an encouraging strategy for bone‐related diseases, such as postmenopausal osteoporosis. In this study, we examined the effects of caffeic acid 3,4‐dihydroxy‐phenethyl ester (CADPE) on osteoclastogenesis. In mouse bone marrow monocytes (BMMs) and RAW264.7 cells, CADPE suppressed RANKL‐induced osteoclast differentiation and actin‐ring formation in a dose‐dependent manner within non–growth inhibitory concentrations at the early stage, while CADPE had no effect on macrophage colony‐stimulating factor (M‐CSF)‐induced proliferation and differentiation. At the molecular level, CADPE inhibited RANKL‐induced phosphorylation of MAPKs, including extracellular signal‐regulated kinases 1/2 (ERK1/2), p38, and c‐Jun N‐terminal kinase (JNK), without significantly affecting the NF‐κB signaling pathway. CADPE abrogated RANKL‐induced activator protein 1 (AP‐1)/FBJ murine osteosarcoma viral oncogene homolog (c‐Fos) nuclear translocation and activation. Overexpression of c‐Fos prevented the inhibition by CADPE of osteoclast differentiation. Furthermore, CADPE suppressed RANKL‐induced the tumor necrosis factor receptor associated factor 6 (TRAF6) interaction with c‐src tyrosine kinase (c‐Src), blocked RANKL‐induced the phosphorylation of protein kinase B (AKT), and inhibited RANKL‐induced Ca 2+ oscillation. As a result, CADPE decreased osteoclastogenesis‐related marker gene expression, including NFATc1 , TRAP , cathepsin K , and c‐Src . To test the effects of CADPE on osteoclast activity in vivo, we showed that CADPE prevented ovariectomy‐induced bone loss by inhibiting osteoclast activity. Together, our data demonstrate that CADPE suppresses osteoclastogenesis and bone loss through inhibiting RANKL‐induced MAPKs and Ca 2+ ‐NFATc1 signaling pathways. CADPE is a novel agent in the treatment of osteoclast‐related diseases, such as osteoporosis. © 2012 American Society for Bone and Mineral Research.

Maackiain dampens osteoclastogenesis via attenuating RANKL‐stimulated NF‐κB signalling pathway and NFATc1 activity

Maackiain dampens osteoclastogenesis via attenuating RANKL-stimulated NF-B signalling pathway and NFATc1 activity

Isoalantolactone Inhibits RANKL-induced Osteoclast Formation Via Multiple Signaling Pathways

Madecassoside Inhibits Estrogen Deficiency‐induced Osteoporosis by Suppressing RANKL‐induced Osteoclastogenesis

Maslinic Acid Suppresses Osteoclastogenesis And Prevents Ovariectomy-Induced Bone Loss By Regulating Rankl-Mediated Nf-Kappa B And Mapk Signaling Pathways

12-Deoxyphorbol 13-Acetate Inhibits RANKL-induced Osteoclastogenesis Via the Attenuation of MAPK Signaling and NFATc1 Activation

Microtubule actin crosslinking factor 1 (MACF1) knockdown inhibits RANKL-induced osteoclastogenesis via Akt/GSK3β/NFATc1 signalling pathway.

Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand-induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+-nuclear fact

Monascin Abrogates RANKL-mediated Osteoclastogenesis in RAW264.7 Cells Via Regulating MAPKs Signaling Pathways.

Maackiain Prevents Amyloid-Beta–Induced Cellular Injury via Priming PKC-Nrf2 Pathway

Angelica Sinensis Extract Inhibits RANKL-mediated Osteoclastogenesis by Down-Regulated the Expression of NFATc1 in Mouse Bone Marrow Cells

Dehydrocostus lactone attenuates osteoclastogenesis and osteoclast-induced bone loss by modulating NF-κB signalling pathway.

Tectorigenin inhibits RANKL-induced osteoclastogenesis via suppression of NF-κB signalling and decreases bone loss in ovariectomized C57BL/6.

Xl019, a Novel JAK Inhibitor, Suppressed Osteoclasts Differentiation Induced by RANKL Through MAPK Signaling Pathway.

Modulating Calcium-Mediated Nfatc1 And Mitogen-Activated Protein Kinase Deactivation Underlies The Inhibitory Effects Of Kavain On Osteoclastogenesis And Bone Resorption

Receptor activator of nuclear factor-κB ligand-mediated osteoclastogenesis signaling pathway and related therapeutic natural compounds

Asperpyrone A Attenuates RANKL-induced Osteoclast Formation Through Inhibiting NFATc1, Ca2+ Signalling and Oxidative Stress.

L-type Ca2+ channel agonist inhibits RANKL-induced osteoclast formation via NFATc1 down-regulation

Cytochalasin Z11 inhibits RANKL-induced osteoclastogenesis via suppressing NFATc1 activation

Deacylcynaropicrin Inhibits RANKL-Induced Osteoclastogenesis by Inhibiting NF-κB and MAPK and Promoting M2 Polarization of Macrophages.